CDK4 and neoplasm: These data demonstrated that applying CDK4/6i strictly as a priming agent could stimulate differentiation into proliferative and effector CD8+T cells in vivo, leading to the anti‐tumor effects observed in the C‐P regimen, while prolonged or later application, as in the C‐PC regimen, could attenuate this effect.